Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...
Read moreSparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...
Read moreSperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...
Read moreLAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...
Read moreThe oversubscribed round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate. Founding investor, BioGeneration Ventures (BGV) and the regional economic ...
Read moreEl “Estudio de inversión en el sector de las ciencias de la vida y la salud en Cataluña 2020” revela la buena salud del ecosistema, que casi ha igualado durante el primer semestre de 2020 el cap...
Read moreRaising private funding is essential for an innovation project to progress and reach market. ITEMAS 2nd webinar of the series about Investment in Covid-19 times tackled the key steps for entrepreneurs...
Read moreOna Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with partici...
Read moreYsios Capital, a leading biotechnology venture capital firm in Spain, today announced its third fund, Ysios BioFund III, with a committed amount of € 155M and a final target size of € 200M.
Read moreAM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human...
Read moreAura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with
Read morePfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease
Read more